钟南山说：疫情会长期_老虎社区_美港股上老虎

2021-05-25

钟南山说：疫情会长期存在！现在的疫苗有效率和有效时间又不太确定！这是否意味着有关疫苗的生物制药公司会长期向好？

麦格理：上调中国生物制药(01177)评级至“跑赢大市” 目标价升24.6%至10.46港元

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":138342312,"tweetId":"138342312","gmtCreate":1621913274636,"gmtModify":1621913274636,"author":{"id":3583530928854592,"authorId":3583530928854592,"authorIdStr":"3583530928854592","name":"人不如故ZM","avatar":"https://static.tigerbbs.com/23a8a73f7c574880f9006fb384657a52","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>钟南山说：疫情会长期存在！现在的疫苗有效率和有效时间又不太确定！这是否意味着有关疫苗的生物制药公司会长期向好？</p></body></html>","htmlText":"<html><head></head><body><p>钟南山说：疫情会长期存在！现在的疫苗有效率和有效时间又不太确定！这是否意味着有关疫苗的生物制药公司会长期向好？</p></body></html>","text":"钟南山说：疫情会长期存在！现在的疫苗有效率和有效时间又不太确定！这是否意味着有关疫苗的生物制药公司会长期向好？","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/138342312","repostId":2138150334,"repostType":2,"repost":{"id":"2138150334","pubTimestamp":1621911235,"share":"https://www.laohu8.com/m/news/2138150334?lang=&edition=full","pubTime":"2021-05-25 10:53","market":"hk","language":"zh","title":"麦格理：上调中国生物制药(01177)评级至“跑赢大市” 目标价升24.6%至10.46港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2138150334","media":"智通财经","summary":"智通财经APP获悉，麦格理发布报告，将中国生物制药评级从“中性”上调至“跑赢大市”，目标价由8.39港元升24.6%至10.46港元。报告中称，公司公布今年首季业绩，来自疫苗业务的盈利非常强劲，预计首季有12亿元人民币利润来自该业务，意味其持股15%同样即将公布业绩的科兴生物首季盈利或达80亿元人民币。麦格理上调公司今明两年每股盈利预测分别62%及33%。","content":"<html><body><p>智通财经APP获悉，麦格理发布报告，将<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>(01177)评级从“中性”上调至“跑赢大市”，目标价由8.39港元升24.6%至10.46港元。</p><p>报告中称，公司公布今年首季业绩，来自疫苗业务的盈利非常强劲，预计首季有12亿元人民币利润来自该业务，意味其持股15%同样即将公布业绩的<a href=\"https://laohu8.com/S/SVA\">科兴生物</a>(SVA.US)首季盈利或达80亿元人民币。</p><p>该行表示，Moderna(MRNA.US)现在疫苗的销售目标为192亿美元，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)目标则为260亿美元，两家企业今年首季的毛利率都有约90%，且销售、一般及行政开支为单位数，预计公司来自疫苗的盈利也会陆续到来。麦格理上调公司今明两年每股盈利预测分别62%及33%。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>麦格理：上调中国生物制药(01177)评级至“跑赢大市” 目标价升24.6%至10.46港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n麦格理：上调中国生物制药(01177)评级至“跑赢大市” 目标价升24.6%至10.46港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 10:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/481045.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，麦格理发布报告，将中国生物制药(01177)评级从“中性”上调至“跑赢大市”，目标价由8.39港元升24.6%至10.46港元。报告中称，公司公布今年首季业绩，来自疫苗业务的盈利非常强劲，预计首季有12亿元人民币利润来自该业务，意味其持股15%同样即将公布业绩的科兴生物(SVA.US)首季盈利或达80亿元人民币。该行表示，Moderna(MRNA.US)现在疫苗的销售目标为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/481045.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","relate_stocks":{"01177":"中国生物制药"},"source_url":"http://www.zhitongcaijing.com/content/detail/481045.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138150334","content_text":"智通财经APP获悉，麦格理发布报告，将中国生物制药(01177)评级从“中性”上调至“跑赢大市”，目标价由8.39港元升24.6%至10.46港元。报告中称，公司公布今年首季业绩，来自疫苗业务的盈利非常强劲，预计首季有12亿元人民币利润来自该业务，意味其持股15%同样即将公布业绩的科兴生物(SVA.US)首季盈利或达80亿元人民币。该行表示，Moderna(MRNA.US)现在疫苗的销售目标为192亿美元，辉瑞(PFE.US)目标则为260亿美元，两家企业今年首季的毛利率都有约90%，且销售、一般及行政开支为单位数，预计公司来自疫苗的盈利也会陆续到来。麦格理上调公司今明两年每股盈利预测分别62%及33%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1105,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":106,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/138342312"}